PharmAthene started at BuyMar. 10, 2014 10:36 AM ET|By: Douglas W. House, SA News Editor H.C. Wainwright initiates coverage of PhamAthene (PIP) with a Buy rating and $4 price target. Bullish outlook based mainly on a successful outcome of its litigation with SIGA Technologies over the small pox antiviral product Arestvyr. Shares currently trade at $1.95. 19 mutual funds have positions, up from 15 a year earlier.